Human papillomavirus type 58 E7 protein (HPV58 E7)

The Human papillomavirus type 58 E7 protein is a small, highly conserved viral oncoprotein (approx. 98 amino acids) encoded by high-risk HPV58. It contains three conserved regions (CR1, CR2, CR3), with the CR3 region encoding a zinc finger motif essential for nuclear localization, protein dimerization, and interactions with host cell cycle regulators[1][3][4]. E7 protein acts by binding and promoting degradation of the retinoblastoma protein (pRb), thereby releasing E2F transcription factors and driving cell proliferation. It also disrupts the DREAM complex and interacts with other regulatory proteins, such as p21, p16^INK4A^, and c-myc, to override cell cycle checkpoints and promote oncogenesis[1][4]. E7 variants with certain amino acid substitutions display increased immortalization and transforming potential, particularly in the context of cervical cancer[1]. The protein's activity is essential for HPV-mediated cellular transformation, persistent infection, and progression to malignancy; as such, it is a high-priority research target for therapeutic vaccine development and molecular diagnostics[1][3][4]. No approved drugs specifically inhibit HPV58 E7, but it remains a model antigen for immunotherapy strategies.

Other names

HPV58 E7E7 protein (HPV type 58)Papillomavirus E7 protein (type 58)

Immune-mediated clearance (vaccines induce E7-specific T cell responses) Inhibition of E7-pRb interaction (hypothetical mechanism for small molecules/peptides) Degradation or destabilization of E7 protein (hypothetical/experimental)